Nontuberculous Mycobacterial Infections Pipeline 2025: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | Insmed Inc, Savara Inc, Paratek Pharma

“Nontuberculous Mycobacterial Infections Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Nontuberculous Mycobacterial Infections Market.

The Nontuberculous Mycobacterial Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Nontuberculous Mycobacterial Infections Pipeline Report:

• Companies across the globe are diligently working toward developing novel Nontuberculous Mycobacterial Infections treatment therapies with a considerable amount of success over the years.

• Nontuberculous Mycobacterial Infections companies working in the treatment market are Insmed Incorporated, Savara Inc, Paratek Pharmaceuticals Inc, LigaChem Biosciences, Inc., Spero Therapeutics, Mannkind Corporation, Pfizer, Agouron Pharmaceuticals, Pharmacia, Janssen Pharmaceutical K.K., and others, are developing therapies for the Nontuberculous Mycobacterial Infections treatment

• Emerging Nontuberculous Mycobacterial Infections therapies in the different phases of clinical trials are- ALIS, Antimycobacterial regimen, Omadacycline Oral Tablet, Delpazolid, SPR720, Clofazimine Inhalation Suspension, Ethambutol hydrochloride, Nelfinavir mesylate, Ethambutol hydrochloride, Bedaquiline, and others are expected to have a significant impact on the Nontuberculous Mycobacterial Infections market in the coming years.

• In May 2025, Paratek Pharmaceuticals will present clinical findings on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference. The data comes from a Phase 2, double-blind, randomized, placebo-controlled, multi-center trial assessing the efficacy, safety, and tolerability of oral omadacycline in adult patients with Nontuberculous Mycobacterial Pulmonary Disease (NTM PD) caused by Mycobacterium abscessus complex (MABc).

• In November 2024, Boston-based Paratek Pharmaceuticals announced positive topline results from a Phase IIb trial assessing its oral antibiotic Nuzyra (omadacycline) in adult patients with nontuberculous mycobacterial (NTM) pulmonary disease. The treatment demonstrated at least a 50% improvement in baseline NTM symptoms without any worsening of existing symptoms. While the study was not designed for formal statistical comparisons between treatment groups, the company highlighted that a consistent trend favoring omadacycline was observed across primary and secondary topline endpoints.

• In October 2024, Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company specializing in rare diseases and multi-drug resistant (MDR) bacterial infections, announced the results of a planned interim analysis from its Phase 2a proof-of-concept study of SPR720 for treating NTM-PD. The analysis revealed that the study did not achieve its primary endpoint. Although SPR720 demonstrated antimicrobial activity, it did not show a significant difference from placebo. Additionally, safety concerns emerged at the 1,000 mg once-daily oral dose, including three cases of reversible grade 3 hepatotoxicity. Considering both efficacy and safety data, the company has decided to suspend the SPR720 development program while assessing alternative strategies.

Nontuberculous Mycobacterial Infections Overview

Nontuberculous Mycobacterial (NTM) infections are caused by a diverse group of mycobacteria found in soil, water, and the environment. Unlike tuberculosis (TB), NTM infections are not contagious and do not spread from person to person. They primarily affect the lungs but can also impact the skin, soft tissues, and lymph nodes.

People with weakened immune systems or underlying lung diseases like chronic obstructive pulmonary disease (COPD) and cystic fibrosis are at a higher risk of developing NTM infections. Symptoms often include chronic cough, fatigue, weight loss, and shortness of breath. Treatment typically involves long-term antibiotic therapy, and in severe cases, surgery may be required.

Get a Free Sample PDF Report to know more about Nontuberculous Mycobacterial Infections Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-pipeline-insight

Emerging Nontuberculous Mycobacterial Infections Drugs Under Different Phases of Clinical Development Include:

• ALIS: Insmed Incorporated

• Antimycobacterial regimen: Savara Inc

• Omadacycline Oral Tablet: Paratek Pharmaceuticals Inc

• Delpazolid: LigaChem Biosciences, Inc.

• SPR720: Spero Therapeutics

• Clofazimine Inhalation Suspension: Mannkind Corporation

• Ethambutol hydrochloride: Pfizer

• Nelfinavir mesylate: Agouron Pharmaceuticals

• Ethambutol hydrochloride: Pharmacia

• Bedaquiline: Janssen Pharmaceutical K.K.

Nontuberculous Mycobacterial Infections Route of Administration

Nontuberculous Mycobacterial Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Nontuberculous Mycobacterial Infections Molecule Type

Nontuberculous Mycobacterial Infections Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Nontuberculous Mycobacterial Infections Pipeline Therapeutics Assessment

• Nontuberculous Mycobacterial Infections Assessment by Product Type

• Nontuberculous Mycobacterial Infections By Stage and Product Type

• Nontuberculous Mycobacterial Infections Assessment by Route of Administration

• Nontuberculous Mycobacterial Infections By Stage and Route of Administration

• Nontuberculous Mycobacterial Infections Assessment by Molecule Type

• Nontuberculous Mycobacterial Infections by Stage and Molecule Type

DelveInsight’s Nontuberculous Mycobacterial Infections Report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Nontuberculous Mycobacterial Infections product details are provided in the report. Download the Nontuberculous Mycobacterial Infections pipeline report to learn more about the emerging Nontuberculous Mycobacterial Infections therapies

Some of the key companies in the Nontuberculous Mycobacterial Infections Therapeutics Market include:

Key companies developing therapies for Nontuberculous Mycobacterial Infections are – Mannkind Corporation, Matinas BioPharma, Spero Therapeutics, Crestone, Inc, Vast Therapeutics, and others.

Nontuberculous Mycobacterial Infections Pipeline Analysis:

The Nontuberculous Mycobacterial Infections pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Nontuberculous Mycobacterial Infections with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Nontuberculous Mycobacterial Infections Treatment.

• Nontuberculous Mycobacterial Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Nontuberculous Mycobacterial Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Nontuberculous Mycobacterial Infections market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Nontuberculous Mycobacterial Infections drugs and therapies

Nontuberculous Mycobacterial Infections Pipeline Market Drivers

• Rising Incidence of NTM Infections, Advancements in Diagnostic Techniques, Increasing Awareness and Screening Programs, Growing Geriatric Population, Ongoing Drug Development and Pipeline Therapies, Rise in Immunocompromised Patients, Government and Private Investments in R&D, are some of the important factors that are fueling the Nontuberculous Mycobacterial Infections Market.

Nontuberculous Mycobacterial Infections Pipeline Market Barriers

• However, Limited Treatment Options, High Cost of Treatment, Lack of Awareness Among Healthcare Providers, Adverse Effects of Long-term Antibiotic Use, Regulatory Challenges and Approval Delays, Limited Commercial Interest, Resistance to Existing Therapies , and other factors are creating obstacles in the Nontuberculous Mycobacterial Infections Market growth.

Scope of Nontuberculous Mycobacterial Infections Pipeline Drug Insight

• Coverage: Global

• Key Nontuberculous Mycobacterial Infections Companies: Insmed Incorporated, Savara Inc, Paratek Pharmaceuticals Inc, LigaChem Biosciences, Inc., Spero Therapeutics, Mannkind Corporation, Pfizer, Agouron Pharmaceuticals, Pharmacia, Janssen Pharmaceutical K.K., and others

• Key Nontuberculous Mycobacterial Infections Therapies: ALIS, Antimycobacterial regimen, Omadacycline Oral Tablet, Delpazolid, SPR720, Clofazimine Inhalation Suspension, Ethambutol hydrochloride, Nelfinavir mesylate, Ethambutol hydrochloride, Bedaquiline, and others

• Nontuberculous Mycobacterial Infections Therapeutic Assessment: Nontuberculous Mycobacterial Infections current marketed and Nontuberculous Mycobacterial Infections emerging therapies

• Nontuberculous Mycobacterial Infections Market Dynamics: Nontuberculous Mycobacterial Infections market drivers and Nontuberculous Mycobacterial Infections market barriers

Request for Sample PDF Report for Nontuberculous Mycobacterial Infections Pipeline Assessment and clinical trials

Table of Contents

1. Nontuberculous Mycobacterial Infections Report Introduction

2. Nontuberculous Mycobacterial Infections Executive Summary

3. Nontuberculous Mycobacterial Infections Overview

4. Nontuberculous Mycobacterial Infections- Analytical Perspective In-depth Commercial Assessment

5. Nontuberculous Mycobacterial Infections Pipeline Therapeutics

6. Nontuberculous Mycobacterial Infections Late Stage Products (Phase II/III)

7. Nontuberculous Mycobacterial Infections Mid Stage Products (Phase II)

8. Nontuberculous Mycobacterial Infections Early Stage Products (Phase I)

9. Nontuberculous Mycobacterial Infections Preclinical Stage Products

10. Nontuberculous Mycobacterial Infections Therapeutics Assessment

11. Nontuberculous Mycobacterial Infections Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Nontuberculous Mycobacterial Infections Key Companies

14. Nontuberculous Mycobacterial Infections Key Products

15. Nontuberculous Mycobacterial Infections Unmet Needs

16 . Nontuberculous Mycobacterial Infections Market Drivers and Barriers

17. Nontuberculous Mycobacterial Infections Future Perspectives and Conclusion

18. Nontuberculous Mycobacterial Infections Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/